Gregory Cairncross

Gregory Cairncross

UNVERIFIED PROFILE

Are you Gregory Cairncross?   Register this Author

Register author
Gregory Cairncross

Gregory Cairncross

Publications by authors named "Gregory Cairncross"

Are you Gregory Cairncross?   Register this Author

99Publications

2384Reads

20Profile Views

Teaching NeuroImages: Collet-Sicard syndrome and hearing loss with glomus jugulotympanicum.

Neurology 2019 Oct;93(14):e1408-e1409

From the Department of Clinical Neurosciences (A.G., Z.A., D.F., J.G.C., S.S.B., S.F.) and Department of Radiology (Z.A.), University of Calgary, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000008205DOI Listing
October 2019

Mutant IDH1 gliomas downregulate phosphocholine and phosphoethanolamine synthesis in a 2-hydroxyglutarate-dependent manner.

Cancer Metab 2018 3;6. Epub 2018 Apr 3.

1Department of Radiology and Biomedical Imaging, University of California San Francisco, 1700 4th Street, Box 2532. Byers Hall 3rd Floor, Suite, San Francisco, CA 94143 USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40170-018-0178-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5881177PMC
April 2018

cIMPACT-NOW update 1: Not Otherwise Specified (NOS) and Not Elsewhere Classified (NEC).

Acta Neuropathol 2018 03 25;135(3):481-484. Epub 2018 Jan 25.

The Brain Tumor Center at Erasmus MC Cancer Center, Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00401-018-1808-0DOI Listing
March 2018

Hyperpolarized (13)C MR imaging detects no lactate production in mutant IDH1 gliomas: Implications for diagnosis and response monitoring.

Neuroimage Clin 2016 23;12:180-9. Epub 2016 Jun 23.

Department of Radiology and Biomedical Imaging, Mission Bay Campus, 1700 4th Street, Byers Hall, University of California, 94158 San Francisco, CA, United States; Brain Tumor Research Center, Helen Diller Family Cancer Research Building, 1450 3rd Street, University of California, 94158 San Francisco, CA, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.nicl.2016.06.018DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4939422PMC
November 2017

Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma.

Neuro Oncol 2017 Oct;19(10):1380-1390

Memorial Sloan Kettering Cancer Center, New York, New York,USA; Northwestern Memorial Hospital, Chicago, Illinois, USA; NorthShore University, Evanston, Illinois,USA; University of Calgary, Calgary, Alberta, Canada; Massachusetts General Hospital, Boston, Massachusetts, USA; MD Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nox086DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5596171PMC
October 2017

Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma.

N Engl J Med 2017 03;376(11):1027-1037

From Odette Cancer Centre, Sunnybrook Health Sciences Centre (J.R.P., A.S.) and Princess Margaret Cancer Centre (N.L., W.P.M.), Toronto, the Canadian Cancer Trials Group, Queens University, Kingston, ON (C.J.O., C.W., K.D.), University of Calgary, Calgary, AB (J.G.C.), University of Alberta, Edmonton (W.R.), Quality of Life Consulting, West Vancouver, BC (D.O.), Queen's University, Kingston General Hospital, Kingston, ON (J.P.R.), and Juravinski Cancer Centre, Hamilton, ON (H.H.) - all in Canada; Azienda Unità Sanitaria Locale- Istituto di Ricovero e Cura a Carattere Scientifico Istituto delle Scienze Neurologiche, Bologna (A.A.B., E.F.), and Fondazione Istituto Neurologico Carlo Besta, Milan (L. Fariselli) - both in Italy; University Hospital Gasthuisberg, Leuven, Belgium (J.M.); Peter MacCallum Cancer Centre, Melbourne, VIC (C.P.), University of Newcastle, Newcastle, NSW (M.F.), University of Queensland, Brisbane (M.F.), and Royal North Shore Hospital, Sydney (M.B.) - all in Australia; Saitama Medical University International Medical Center, Saitama, Japan (R.N.); Hôpital de la Pitié-Salpêtrière (F.L.-D., L. Feuvret), Paris, and Aix-Marseille University, Assistance Publique-Hôpitaux de Marseille, Centre Hospitalier Universitaire Timone, Marseilles (O.C.) - both in France; the European Organization for Research and Treatment of Cancer, Brussels (V.G.); the Neurology Clinic, University of Heidelberg, Heidelberg, Germany (A.W., W.W.); Tauranga Hospital, Tauranga, New Zealand (M.T.); and Maastricht University Medical Center and School for Oncology and Developmental Biology, Maastricht, the Netherlands (B.G.B.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1611977DOI Listing
March 2017

Disulfiram when Combined with Copper Enhances the Therapeutic Effects of Temozolomide for the Treatment of Glioblastoma.

Clin Cancer Res 2016 08 22;22(15):3860-75. Epub 2016 Mar 22.

Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada. Clark H. Smith Brain Tumour Centre, University of Calgary, Calgary, Alberta, Canada. Department of Oncology, University of Calgary, Calgary, Alberta, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-1798DOI Listing
August 2016

IDH1 Mutation Induces Reprogramming of Pyruvate Metabolism.

Cancer Res 2015 Aug 4;75(15):2999-3009. Epub 2015 Jun 4.

Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-15-0840DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4526330PMC
August 2015

Precursor States of Brain Tumor Initiating Cell Lines Are Predictive of Survival in Xenografts and Associated with Glioblastoma Subtypes.

Stem Cell Reports 2015 Jul 18;5(1):1-9. Epub 2015 Jun 18.

Hotchkiss Brain Institute, Department of Cell Biology and Anatomy, University of Calgary, Calgary, AB T2N 4N1, Canada; Southern Alberta Cancer Research Institute, University of Calgary, Calgary, AB T2N 4N1, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.stemcr.2015.05.010DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4618251PMC
July 2015

Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors.

Neuro Oncol 2014 Nov 4;16(11):1541-6. Epub 2014 Jul 4.

Departments of Neurology (A.B.L., F.M.I., L.E.A., L.M.D.), Pathology (S.C.J., M.K.R.), Epidemiology & Biostatistics (A.S.R., K.S.P.), and the Brain Tumor Center, Memorial Sloan-Kettering Cancer Center, New York, New York; University of California, Los Angeles, Los Angeles, California (T.F.C.); Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas (K.D.A., A.L.R.); Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts (A.F.E., D.N.L.); NorthShore University Health System, Evanston Hospital Kellogg Cancer Center, University of Chicago, Pritzker School of Medicine, Evanston, Illinois (N.A.P.); London Regional Cancer Program, London, Ontario, Canada (B.J.F.); Barrow Neurological Institute, Phoenix, Arizona (L.S.A.); University of Calgary, Calgary, Alberta, Canada (J.G.C., G.B.R.U.); Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, Massachusetts (P.Y.W.); Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Children's Hospital Boston, Brigham and Women's Hospital, Boston, Massachusetts (K.L.L.); University of Virginia Health System, Charlottesville, Virginia (D.S.); University of Wisconsin, Madison, Wisconsin (H.I.R., B.G.R.); University of Washington, Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance, Seattle, Washington (M.C.C.); Princess Margaret Hospital, Toronto, Ontario, Canada (W.P.M.); Albany Medical Center, Albany, New York (S.A.W.); Kaiser Permanente-Los Angeles Medical Center, Los Angeles, California (R.M.G.); Clemenceau Medical Center, Beirut, Lebanon and Université Saint-Esprit de Kaslik, Byblos, Lebanon (F.G.K.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nou083DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4201067PMC
November 2014

Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.

Clin Cancer Res 2014 Nov 14;20(22):5756-67. Epub 2014 Oct 14.

Hotchkiss Brain Institute, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada. Department of Cell Biology and Anatomy, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada. Clark Smith Brain Tumour Research Centre, Southern Alberta Cancer Research Institute, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-13-3389DOI Listing
November 2014

Novel MSH6 mutations in treatment-naïve glioblastoma and anaplastic oligodendroglioma contribute to temozolomide resistance independently of MGMT promoter methylation.

Clin Cancer Res 2014 Sep 30;20(18):4894-903. Epub 2014 Jul 30.

Hotchkiss Brain Institute, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada. Department of Cell Biology and Anatomy, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada. Clark Smith Brain Tumor Research Centre, Southern Alberta Cancer Research Institute, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-13-1856DOI Listing
September 2014

Mutations in CIC and IDH1 cooperatively regulate 2-hydroxyglutarate levels and cell clonogenicity.

Oncotarget 2014 Sep;5(17):7960-79

Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, BC, Canada. Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4202173PMC
http://dx.doi.org/10.18632/oncotarget.2401DOI Listing
September 2014

Lactate dehydrogenase A silencing in IDH mutant gliomas.

Neuro Oncol 2014 May 22;16(5):686-95. Epub 2013 Dec 22.

Department of Clinical Neurosciences, Foothills Hospital, Calgary, Alberta, Canada (C.C., M.D.B., M.A.-N., J.A.C., S.W., J.G.C.); Department of Cell Biology and Anatomy, Health Research Innovation Centre, Calgary, Alberta, Canada (O.D.S., S.W., H.A.L.); Department of Pathology & Laboratory Medicine, Foothills Hospital, Calgary, Alberta, Canada (J.A.C.); Southern Alberta Cancer Research Institute, Health Research Innovation Centre, Calgary, Alberta, Canada (C.C., M.D.B., M.A.-N., J.A.C., S.W., H.A.L., J.G.C.); Hotchkiss Brain Institute, Health Research Innovation Centre, Calgary, Alberta, Canada (O.D.S., S.W., H.A.L.); Department of Radiology and Biomedical Imaging, San Francisco, California (M.M.C., S.M.R.); Brain Tumor Research Center, Department of Neurological Surgery, San Francisco, California (R.O.P).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/not243DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3984548PMC
May 2014

Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH.

J Clin Oncol 2014 Mar 10;32(8):783-90. Epub 2014 Feb 10.

J. Gregory Cairncross, University of Calgary, Calgary, Alberta; Luis Souhami, McGill University, Montreal, Quebec; Normand J. Laperriere, University of Toronto, Toronto, Ontario, Canada; Meihua Wang, American College of Radiology, Philadelphia, PA; Robert B. Jenkins, Caterina Giannini, and Jan C. Buckner, Mayo Clinic, Rochester, MN; Edward G. Shaw, Wake Forest School of Medicine, Winston-Salem, NC; David G. Brachman, Arizona Oncology Services Foundation/Barrow Neurological Institute, Phoenix, AZ; Karen L. Fink, Baylor University, Dallas, TX; Jason T. Huse, Memorial Sloan-Kettering Cancer Center, New York, NY; Minesh P. Mehta, Northwestern University, Chicago, IL; and Walter J. Curran Jr, Emory University, Atlanta, GA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.49.3726DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3940537PMC
March 2014

A novel C19MC amplified cell line links Lin28/let-7 to mTOR signaling in embryonal tumor with multilayered rosettes.

Neuro Oncol 2014 Jan 4;16(1):62-71. Epub 2013 Dec 4.

Corresponding authors: Jennifer A. Chan, MD, Department of Pathology & Laboratory Medicine, University of Calgary, HRIC 2A25, 3330 Hospital Drive NW, Calgary, Alberta, Canada T2N 4N1. Annie Huang, MD, PhD, Division of Hematology-Oncology, Department of Pediatrics, The Hospital for Sick Children, TMDT, 11-401P, 101 College St., Toronto, Ontario, Canada M5G 1L7

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/not162DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3870842PMC
January 2014

Therapeutic activation of macrophages and microglia to suppress brain tumor-initiating cells.

Nat Neurosci 2014 Jan 8;17(1):46-55. Epub 2013 Dec 8.

1] Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada. [2] Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nn.3597DOI Listing
January 2014

Leptomeningeal disease in oligodendroglial tumors: a population-based study.

J Neurooncol 2011 Sep 4;104(3):811-5. Epub 2011 Mar 4.

Clark H. Smith Brain Tumor Center, Tom Baker Cancer Center, Alberta Health Services, HRIC 2AA07, 3330 Hospital Dr NW, Calgary, AB, T2N 4N1, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-011-0551-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3170119PMC
September 2011

Do epileptic seizures predict outcome in patients with oligodendroglioma?

Epilepsy Res 2011 Mar 18;94(1-2):39-44. Epub 2011 Feb 18.

Department of Clinical Neurological Sciences, University of Western Ontario, London, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eplepsyres.2011.01.001DOI Listing
March 2011

Sensitivity to temozolomide in brain tumor initiating cells.

Neuro Oncol 2010 Jul 13;12(7):756-60. Epub 2010 Apr 13.

Department of Clinical Neurosciences, Foothills Medical Centre, 1403 29th St NW, Calgary, Alberta, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noq032DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2940656PMC
July 2010

Predicting MGMT methylation status of glioblastomas from MRI texture.

Med Image Comput Comput Assist Interv 2009 ;12(Pt 2):522-30

Department of Radiology, University of Calgary, Alberta, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-642-04271-3_64DOI Listing
June 2010

Separating the wheat from the chaff: the search for truly informative biomarkers.

Neurology 2010 Jun 5;74(23):1848-9. Epub 2010 May 5.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0b013e3181e475b7DOI Listing
June 2010

Use of peri-operative anti-epileptic drugs in patients with newly diagnosed high grade malignant glioma: a single center experience.

J Neurooncol 2010 Feb 8;96(3):403-8. Epub 2009 Aug 8.

Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-009-9977-2DOI Listing
February 2010

An analysis of image texture, tumor location, and MGMT promoter methylation in glioblastoma using magnetic resonance imaging.

Neuroimage 2010 Jan 28;49(2):1398-405. Epub 2009 Sep 28.

Department of Electrical and Computer Engineering, University of Calgary, Alberta, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neuroimage.2009.09.049DOI Listing
January 2010

Adult supratentorial low-grade glioma: long-term experience at a single institution.

Int J Radiat Oncol Biol Phys 2009 Dec 22;75(5):1401-7. Epub 2009 Apr 22.

Department of Oncology, London Health Sciences Center, University of Western Ontario, London, ON, Canada.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S036030160900084
Publisher Site
http://dx.doi.org/10.1016/j.ijrobp.2009.01.010DOI Listing
December 2009

Population-based study of pseudoprogression after chemoradiotherapy in GBM.

Can J Neurol Sci 2009 Sep;36(5):617-22

Department of Oncology, Tom Baker Cancer Centre, Alberta Cancer Board, Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada.

View Article

Download full-text PDF

Source
http://www.bvsoncologia.org.uy/pdfs/urucan/canjneurolsci3661
Web Search
http://dx.doi.org/10.1017/s0317167100008131DOI Listing
September 2009

Gliomas with 1p/19q codeletion: a.k.a. oligodendroglioma.

Cancer J 2008 Nov-Dec;14(6):352-7

Department of Clinical Neurosciences and Hotchkiss Brain, Institute, University of Calgary, Calgary, Alberta, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PPO.0b013e31818d8178DOI Listing
February 2009

Glioblastoma in the elderly: an age-old problem.

Ann Neurol 2008 Dec;64(6):597-9

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ana.21560DOI Listing
December 2008

Methylation status of MGMT gene promoter in meningiomas.

Cancer Genet Cytogenet 2008 Nov;187(1):25-7

Department of Clinical Neurosciences, University of Calgary, Alberta, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cancergencyto.2008.07.006DOI Listing
November 2008

Toxicity from chemoradiotherapy in older patients with glioblastoma multiforme.

J Neurooncol 2008 Aug 9;89(1):97-103. Epub 2008 Apr 9.

Department of Neurology, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11060-008-9593-6
Publisher Site
http://dx.doi.org/10.1007/s11060-008-9593-6DOI Listing
August 2008

Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402.

Brain Pathol 2008 Jul 26;18(3):360-9. Epub 2008 Mar 26.

Division of Anatomic Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1750-3639.2008.00129.xDOI Listing
July 2008

Invited article: the expanding impact of molecular biology on the diagnosis and treatment of gliomas.

Neurology 2008 Jul;71(5):365-73

Department of Medicine, the University of Toronto, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/01.wnl.0000319721.98502.1bDOI Listing
July 2008

Leptomeningeal disease from oligodendroglioma: clinical and molecular analysis.

Can J Neurol Sci 2008 May;35(2):204-9

Department of Oncology, Tom Baker Cancer Centre, Alberta Cancer Board, University of Calgary, Calgary, Alberta. Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1017/s0317167100008647DOI Listing
May 2008

Population-based study of medulloblastoma: outcomes in Alberta from 1975 to 1996.

Can J Neurol Sci 2008 May;35(2):210-5

Department of Clinical Neurosciences, Foothills Medical Centre, University of Calgary, Calgary, Alberta, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1017/s0317167100008659DOI Listing
May 2008

Tests of association under misclassification: application to histological sampling in oncology.

Stat Med 2007 Nov;26(26):4808-16

Department of Biostatistics, Harvard School of Public Health, 655 Huntington Ave, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/sim.2895
Publisher Site
http://dx.doi.org/10.1002/sim.2895DOI Listing
November 2007

Adjuvant chemotherapy for adults with malignant glioma: a systematic review.

Can J Neurol Sci 2007 Nov;34(4):402-10

Odette Cancer Centre, Sunnybrook Health Sciences Centre Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1017/s0317167100007265DOI Listing
November 2007

O6-methylguanine-DNA methyltransferase regulation by p53 in astrocytic cells.

Cancer Res 2007 Jan;67(2):580-4

Department of Clinical Neurosciences, University of Calgary and the Southern Alberta Cancer Research Institute, Calgary, Alberta, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-06-2782DOI Listing
January 2007

Changing paradigms--an update on the multidisciplinary management of malignant glioma.

Oncologist 2006 Feb;11(2):165-80

Multidisciplinary Oncology Center, University of Lausanne Hospitals, 46 Rue du Bugnon, Lausanne 1011, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.11-2-165DOI Listing
February 2006

Drug Insight: temozolomide as a treatment for malignant glioma--impact of a recent trial.

Nat Clin Pract Neurol 2005 Dec;1(2):88-95

Princess Margaret Hospital, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncpneuro0045DOI Listing
December 2005

Inactivation of p53 sensitizes astrocytic glioma cells to BCNU and temozolomide, but not cisplatin.

J Neurooncol 2005 Sep;74(2):141-9

Department of Oncology, University of Western Ontario, London, Ontario, Canada.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11060-004-6601-3
Publisher Site
http://dx.doi.org/10.1007/s11060-004-6601-3DOI Listing
September 2005

Pharmaceutical-mediated inactivation of p53 sensitizes U87MG glioma cells to BCNU and temozolomide.

Int J Cancer 2005 Aug;116(2):187-92

Department of Oncology, University of Western Ontario, London, Ontario.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/ijc.21071
Publisher Site
http://dx.doi.org/10.1002/ijc.21071DOI Listing
August 2005

Imaging molecular signatures in oligodendroglioma.

Clin Cancer Res 2004 Nov;10(21):7109-11

Department of Clinical Neurosciences, University of Calgary and Tom Baker Cancer Centre, Calgary, Alberta, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-04-2018DOI Listing
November 2004

Imaging correlates of molecular signatures in oligodendrogliomas.

Clin Cancer Res 2004 Jul;10(13):4303-6

Department of Clinical Neurological Sciences, University of Western Ontario and London Regional Cancer Centre, London, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-04-0209DOI Listing
July 2004

Long-term survivors of glioblastoma: statistical aberration or important unrecognized molecular subtype?

Cancer J 2003 May-Jun;9(3):214-21

Department of Oncology & Clinical Neurosciences, University of Calgary and Tom Baker Cancer Centre, Calgary, Alberta.

View Article

Download full-text PDF

Source
December 2003

Glioma therapies: how to tell which work?

J Clin Oncol 2003 Oct 11;21(19):3547-9. Epub 2003 Aug 11.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2003.05.885DOI Listing
October 2003

Gene expression-based classification of malignant gliomas correlates better with survival than histological classification.

Cancer Res 2003 Apr;63(7):1602-7

Department of Pathology and Neurosurgical Service, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA.

View Article

Download full-text PDF

Source
April 2003

Recent developments in the molecular characterization and treatment of oligodendroglial tumors.

Neuro Oncol 2003 04;5(2):128-38

Department of Neuro-Oncology, Dr. Daniel den Hoed Cancer Center, 3008 AE Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1920673PMC
http://dx.doi.org/10.1215/s1522-8517-02-00028-5DOI Listing
April 2003

Analysis of a molecular genetic neuro-oncology study with partially biased selection.

Biostatistics 2003 Apr;4(2):167-78

Department of Biostatistics, Harvard School of Public Health, 655 Huntington Avenue, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/biostatistics/4.2.167DOI Listing
April 2003

Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review.

Radiother Oncol 2002 Sep;64(3):259-73

Department of Radiation Oncology, Princess Margaret Hospital/University Health Network, University of Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0167-8140(02)00078-6DOI Listing
September 2002

Acetazolamide therapy for symptomatic plateau waves in patients with brain tumors. Report of three cases.

J Neurosurg 2002 Jul;97(1):224-6

Department of Clinical Neurological Sciences, University of Western Ontario, London, Canada.

View Article

Download full-text PDF

Source
https://thejns.org/view/journals/j-neurosurg/97/1/article-p2
Publisher Site
http://dx.doi.org/10.3171/jns.2002.97.1.0224DOI Listing
July 2002

Influence of unrecognized molecular heterogeneity on randomized clinical trials.

J Clin Oncol 2002 May;20(10):2495-9

Department of Biostatistics, Harvard School of Public Health, 655 Huntington Avenue, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2002.06.140DOI Listing
May 2002

The use of frailty hazard models for unrecognized heterogeneity that interacts with treatment: considerations of efficiency and power.

Biometrics 2002 Mar;58(1):232-6

Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
March 2002

DMBT1 polymorphisms: relationship to malignant glioma tumorigenesis.

Cancer Res 2002 Mar;62(6):1790-6

Molecular Neuro-Oncology and Pathology Laboratories, Department of Pathology and Neurosurgical Service, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02129, USA.

View Article

Download full-text PDF

Source
March 2002

Ki-67: a prognostic factor for low-grade glioma?

Int J Radiat Oncol Biol Phys 2002 Mar;52(4):996-1001

Department of Radiation Oncology, London Regional Cancer Centre and University of Western Ontario, London, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0360-3016(01)02720-1DOI Listing
March 2002

Focus on central nervous system neoplasia.

Cancer Cell 2002 Mar;1(2):125-8

Department of Pathology and Neurosurgical Service, Massachusetts General Hospital, Boston, MA 02114, USA.

View Article

Download full-text PDF

Source
March 2002

A better way to find tumor in the CSF?

Neurology 2002 Feb;58(3):339-40

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/wnl.58.3.339DOI Listing
February 2002

Histopathological-molecular genetic correlations in referral pathologist-diagnosed low-grade "oligodendroglioma".

J Neuropathol Exp Neurol 2002 Jan;61(1):58-63

Department of Pathology and Neurosurgical Service, Massachusetts General Hospital and Harvard Medical School, Boston, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnen/61.1.58DOI Listing
January 2002